InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,543.22
(
1.61%
)
US TECH 100
19,002.00
(
2.66%
)
Dow Jones
40,563.06
(
1.39%
)
Brent Oil
80.39
(
-0.11%
)
Bitcoin
58,175.40
(
1.10%
)
Post# of 130513
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Solantey

Send PM Follow Ignore
Followers 53
Posts 4314
Boards Moderated 0
Alias Born 02/28/2010

Solantey

Re: None

Sunday, 06/22/2014 2:08:01 AM

Sunday, June 22, 2014 2:08:01 AM

Post# of 130513
Immediate opportunity for LymPro:

322 Studies Currently for Drugs In Development for Alzheimer's:

http://clinicaltrials.gov/ct2/results?term=Alzheimer&recr=Open&no_unk=Y&pg=1
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

FEATURED POET Technologies Reports Second Quarter 2024 Financial Results • Aug 15, 2024 8:04 AM

PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM

VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM

Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM

Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM

ATWEC Reaches Profitability, Announces Massive Earnings Growth, and a Strong Forecast for the Rest of 2024 • ATWT • Aug 15, 2024 7:16 AM

Start posting your company's news
Only $200 per official company press release!